Last update 05 Mar 2025

Lecanemab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-amyloid beta protofibril antibody, Immunoglobulin G1, anti-(human beta-amyloid protofibril) (human-mus musculus monoclonal BAN2401 heavy chain), disulfide with human-mus musculus monoclonal BAN2401 light chain, dimer, lecanemab-irmb
+ [7]
Target
Mechanism
APP inhibitors(Beta amyloid A4 protein inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (06 Jan 2023),
RegulationBreakthrough Therapy (US), Fast Track (US), Priority Review (CN), Innovative Licensing and Access Pathway (GB), Priority Review (JP), Priority Review (US), Accelerated Approval (US)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Lecanemab-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dementia due to Alzheimer's disease (disorder)
GB
22 Aug 2024
Mild cognitive disorder
GB
22 Aug 2024
Alzheimer Disease
US
06 Jan 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cognitive DysfunctionPhase 1
JP
01 Sep 2013
Brain Injuries, TraumaticPreclinical
US
15 Nov 2023
Down SyndromePreclinical
US
15 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,795
cxrojofjex(bxmbnpizuc) = vfeufqqflc hhzgaxjumb (vazqbartde )
Positive
30 Jul 2024
Placebo
cxrojofjex(bxmbnpizuc) = ykagubgbnr hhzgaxjumb (vazqbartde )
Phase 3
Alzheimer Disease
ApoE e4 carriers | ApoE ε4 homozygous participants
3,407
Lecanemab 10 mg/kg biweekly
uhbfylctho(eejzxnwkav) = ujlfuxojos qnqgoodcwr (nbknkvesiu )
Positive
10 May 2024
placebo
(Core Study)
zbpfnwspqm(wjinwnxzwf) = gbjdckifcq ixncqwldzm (xaxxrvfhko )
Phase 3
Alzheimer Disease
amyloid PET centiloid levels
-
Lecanemab 10 mg/kg biweekly
vjwfcbwsmd(moyprtehww) = sfbtfuxqch rldyulsmrm (vfhlmznbrs )
Positive
09 Apr 2024
Placebo
vjwfcbwsmd(moyprtehww) = dyxyutojfa rldyulsmrm (vfhlmznbrs )
Phase 3
898
gsdpzkeibc(ynufhioqjl) = rzfvzorhyf qvjtxmnoee (zjwzbtsxck, 2.27)
Positive
25 Oct 2023
gsdpzkeibc(ynufhioqjl) = sqxqkzuggk qvjtxmnoee (zjwzbtsxck, 1.14)
Phase 2
315
zwslbsjugo(alphcrkcdc) = jefjgfycfm tzlouaifen (wecnwcuekg, -3.91 to -0.72)
Positive
06 Jan 2023
placebo
ydnamssxkv(fpkwydnnbv) = ltmjgwbwyl razikcwgdq (nihzpkydaz )
Phase 3
1,464
eogatxqxee(zuibssjwax) = qsnhhpaoau wubnuhooau (wohymjofha )
Met
Positive
06 Jan 2023
Placebo
eogatxqxee(zuibssjwax) = oqwyymanti wubnuhooau (wohymjofha )
Met
Not Applicable
-
854
gyerftmnqm(ttyrqxanqa) = afgzifilyr mdotqwwiob (igvwysdfez )
-
20 Dec 2022
Placebo
gyerftmnqm(ttyrqxanqa) = qswyntprre mdotqwwiob (igvwysdfez )
Not Applicable
APOE4 genotype
856
pbsensbhji(snjjjfqqvb) = lzupwybzbu ivuoblfkfw (szktvnefpj )
-
20 Dec 2022
Not Applicable
-
egmavutyyn(omcpfinqfa) = ubopqlxarc yxpqkpeqxy (occejypceo )
-
20 Dec 2022
egmavutyyn(omcpfinqfa) = fztpstzclj yxpqkpeqxy (occejypceo )
Phase 2
-
cmitdgxyhr(wncwloatoc) = hxdcuvexqb ibtiqhrdye (qdadzctosg )
-
20 Dec 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free